At5g62930 Antibody

Shipped with Ice Packs
In Stock

Description

Definition and Biological Context

At5g62930 Antibody is a specialized immunological reagent targeting the protein encoded by the At5g62930 gene in Arabidopsis thaliana (thale cress). This gene encodes an SGNH hydrolase-type esterase, a class of enzymes involved in lipid metabolism and plant defense mechanisms . The antibody is designed to detect and bind specifically to this protein, enabling researchers to study its expression, localization, and functional roles in plant biology.

Role of At5g62930 in Plant Biology

The At5g62930 protein belongs to the SGNH hydrolase superfamily, which is characterized by conserved serine, glycine, asparagine, and histidine residues critical for catalytic activity . These enzymes are implicated in:

  • Lipid metabolism: Hydrolysis of ester bonds in fatty acid derivatives .

  • Stress responses: Modulating plant defense against pathogens .

  • Cell wall remodeling: Facilitating structural changes during growth .

Antibody Validation and Cross-Reactivity

  • Specificity: The antibody binds selectively to the At5g62930 epitope, as demonstrated in Western blot analyses of Arabidopsis extracts .

  • Cross-Reactivity: No significant cross-reactivity with homologous proteins (e.g., At5g03610 or At4g28780) has been reported .

Protein Localization Studies

The At5g62930 Antibody has been employed to map the subcellular distribution of the protein in Arabidopsis tissues. Immunohistochemical assays reveal strong signals in vascular tissues and root meristems, suggesting roles in nutrient transport and developmental regulation .

Transcriptional Regulation Analysis

Promoter-binding studies using transgenic Arabidopsis lines indicate that At5g62930 expression is influenced by cytokinin signaling pathways. The antibody aids in tracking protein levels under hormonal treatments .

Comparative Genomics

Comparative analyses in pecan (Carya illinoinensis) identified orthologs of At5g62930 (e.g., CilGDSL27.35), highlighting conserved functions across plant species .

Stress Adaptation

  • Cold Tolerance: Knockout mutants of At5g62930 exhibit delayed senescence under cold stress, implicating the protein in stress resilience .

  • Pathogen Response: SGNH hydrolases like At5g62930 are upregulated during fungal infections, suggesting a role in hydrolyzing pathogen-derived lipids .

Metabolic Pathways

Enzymatic assays using purified At5g62930 protein demonstrate activity against acetylated xyloglucans, linking it to cell wall modification .

Limitations and Future Directions

  • Limitations: No monoclonal version is currently available, limiting high-throughput applications .

  • Future Research: Structural characterization of the At5g62930-antigen complex could refine antibody specificity .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
At5g62930 antibody; MQB2.25GDSL esterase/lipase At5g62930 antibody; EC 3.1.1.- antibody
Target Names
At5g62930
Uniprot No.

Q&A

FAQs for Researchers on At5g62930 Antibody

Advanced Research Questions

  • How to resolve contradictions between antibody performance in Western blot vs. flow cytometry?

    • Methodology:

      • Hypothesis: Post-translational modifications (e.g., glycosylation) may alter epitope accessibility. Test deglycosylation (e.g., PNGase F treatment) in Western blot and compare with flow cytometry results .

      • Experimental design:

        Assay TypeGlycosylation StatusAntibody Binding (Relative Intensity)
        WesternNative1.0
        WesternDeglycosylated0.2
        Flow CytometryNative0.8
  • What strategies improve antibody-dependent cellular cytotoxicity (ADCC) for therapeutic At5g62390-targeting antibodies?

    • Methodology:

      • Engineer Fc regions to enhance FcγRIIIa binding (e.g., afucosylation) .

      • Validate ADCC potency using NK cell co-culture assays with target cells expressing At5g62390 .

      • Compare with benchmark antibodies (e.g., benralizumab analogue) to assess relative efficacy .

Troubleshooting & Data Analysis

  • How to address nonspecific binding in immunohistochemistry (IHC) with At5g62390 antibodies?

    • Methodology:

      • Pre-absorb antibodies with tissue lysates lacking At5g62390 (e.g., CRISPR knockout tissues) .

      • Use blocking peptides matching the At5g62390 epitope to competitively inhibit binding .

  • What computational tools predict At5g62390-antibody binding dynamics?

    • Methodology:

      • Apply inverse folding models (e.g., IgDesign) to simulate CDR-antigen interactions and optimize binding affinity .

      • Validate predictions with surface plasmon resonance (SPR) to measure kinetic parameters (KD, kon/koff) .

Experimental Design

  • How to standardize At5g62390 antibody dilution across assays?

    • Methodology:

      • Perform checkerboard titrations in pilot experiments:

        DilutionWestern SignalBackground Noise
        1:500HighModerate
        1:1000ModerateLow
        1:2000LowNegligible
      • Use nonlinear regression to identify the optimal signal-to-noise ratio .

  • How to validate antibody functionality in 3D cell culture models?

    • Methodology:

      • Test antibody penetration in tumor spheroids using fluorescently labeled At5g62390 antibodies and confocal microscopy .

      • Compare cytotoxicity in 2D monolayers vs. 3D cultures using ATP-based viability assays .

Key Considerations:

  • Cross-reactivity: Always pair antibody validation with orthogonal techniques (e.g., CRISPR validation + mass spectrometry) .

  • Assay context: Antibody performance may vary between denatured (Western) vs. native (flow cytometry/IHC) conditions .

  • Therapeutic potential: Prioritize antibodies with dual mechanisms (e.g., ADCC enhancement and receptor blockade) .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.